AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
1. AbbVie reported Q1 EPS of $2.46, beating estimates by $0.08. 2. Sales of $13.34 billion exceeded forecasts, driven by strong immunology performance. 3. Immunology drugs Skyrizi and Rinvoq see significant revenue growth expectations by 2027. 4. Humira sales decline drastically, but overall growth remains promising. 5. Analysts maintain positive outlook despite potential macroeconomic challenges.